\(^O^)/ try 1ClickFB.com download facebook videos

Dr. West on FDA Approval of Frontline Alectinib in ALK+ NSCLC

Say and pronounce Dr. West On on SuperTTS.com Make Your Own Text-To-Speech Words Instantly

  Info

Description

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the FDA approval of alectinib (Alecensa) as a first-line treatment for patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC).

Tags

cancer oncology
  Email Video to Friends   Receive Emails for Similar Videos

Email:

  Repeat and Loop Video   Link to Video   Create Short URL  Publish Text About This Video   Share on Facebook, Twitter, and more
  See Recommended Videos For You
Old Cartoons on DVD. Visit and Bookmark: Cool90s.com!

Related

  Dr. Neal Debates Whether Alectinib Will Become the Standard Frontline Thera for ALK+ NSCLC   Dr. West on FDA Approval of Brigatinib in ALK+ NSCLC   FDA Approval: Frontline Ceritinib for ALK+ NSCLC   Dr. Wakelee on FDA Approval of Frontline Pembrolizumab in NSCLC   Dr. Villaflor Discusses Alectinib in ALK+ NSCLC   Dr. Shaw on the Phase III Results of the ALEX Trial in NSCLC   FDA Approval of Brigatinib for ALK+ NSCLC   Dr. Spigel on FDA Approval of Pembrolizumab/Chemo Combo in NSCLC   Dr. Velcheti on Potential of Alectinib in Frontline ALK-Positive NSCLC   Ceritinib and Alectinib in Relapsed ALK+ NSCLC   Alectinib for Relapsed/Refractory ALK+ NSCLC   FDA Approval in Carcinoid Syndrome Diarrhea, Priority Reviews in Bladder Cancer and NSCLC, and More   Upfront Use of Next-Generation ALK Inhibitors in NSCLC   FDA Approval in MZL, Delay in Immunotherapy Combos in NSCLC, and 2017 GI Symposium Highlights   Evolving Approaches for Treating ALK-Positive NSCLC   FDA Approves Frontline Nivolumab for Advanced Melanoma   Next-Generation ALK Inhibitors for NSCLC   FDA Approval of Atezolizumab for NSCLC   Progression of ALK+ NSCLC   Dr. McKay on FDA Approval of Nivolumab/Ipilimumab in Frontline RCC   Dr. Siefker-Radtke on FDA Approval of Frontline Atezolizumab in Bladder Cancer   Dr. Gandhi on Sequencing and Emerging Agents in ALK+ NSCLC   Dr. Gandhi on Pembrolizumab/Chemo Findings in NSCLC and FDA Approval   Treatment of Relapsed/Refractory ALK+ NSCLC   Dr. Brammer on FDA Approval of Brentuximab Vedotin in CTCL   ALK Inhibitor Sequencing in NSCLC   Sequencing Therapies in ALK+ NSCLC   Dr. Garcia on FDA Approval of Pembrolizumab in Bladder Cancer   Dr. Mok on Breakthrough Therapies for ALK-Positive NSCLC   Dr. Bendell on FDA Approval of Regorafenib in Liver Cancer   Dr. Al-Kali on FDA Approval of Enasidenib in AML   Dr. Straus on FDA Approval of Pembrolizumab in Hodgkin Lymphoma   Dr. Suresh Ramalingam on Frontline Osimertinib Data in EGFR+ NSCLC   Dr. West on Emerging Changes in the Field of EGFR-Mutant NSCLC   Review on 2016 FDA Approvals, Halt on AML Trials, and More   Frontline ALK, EGFR Inhibition in Non-Small Cell Lung Cancer   Dr. Kelly on the FDA Approval of Ribociclib in HR+ Breast Cancer   Dr. Ramalingam on FLAURA Findings in EGFR-Mutant NSCLC   Dr. Costin on Frontline Immunotherapy for Patients With NSCLC   Development of ALK-Targeted Therapy for NSCLC   Dr. Gubens on Prevalence of EGFR/ALK/ROS1 and PD-L1 Expression in NSCLC   Crizotinib for ALK-Rearranged NSCLC   Breakthrough In Leukemia Treatment   EGFR & ALK/ROS1 Testing in Squamous NSCLC   New drug trial heals dogs of arthritis   Treatment of ALK-Driven Refractory NSCLC   Clarence-based company could become first to sell very low nicotine cigarette   Future Directions for ALK+ NSCLC   Dr. Joel Neal on Impact of PD-L1 Tests on Pembrolizumab, Nivolumab Efficacy in Frontline NSCLC   Next-Generation ALK-Targeted Agents in NSCLC   Upfront Use of Second-Generation TKIs in ALK+ NSCLC   ALTA II Trial of Brigatinib in ALK-Rearranged NSCLC   The Evolution of ALK/ROS1-Targeted Therapy in NSCLC   Upfront Use of Second-Line Agents in ALK+ NSCLC   Extended Cut: Should the Terminally Ill Have the Right to Try, Non FDA Approved Drugs?   Durvalumab FDA Approval for Bladder Cancer   Patterns of Progression on Crizotinib for ALK+ NSCLC   The FDA Approval of Atezolizumab in Bladder Cancer   New cancer treatment offers patients hope   Novartis Metastatic Breast Cancer Treatment   Cancer Advance of the Year, FDA Approval for CINV, Breakthrough Designation in TNBC, And More   Experience with Ceritinib for ALK+ NSCLC   Choosing Second-Line Therapy for ALK+ NSCLC   Next Generation ALK Inhibitors for NSCLC   Ceritinib Alternative Dosing for ALK+ NSCLC   Third-Generation ALK Inhibitors for NSCLC   FDA Approval in AML, Priority Review Designation in NSCLC, and More   Dr. Govindan on the Potential for Alectinib   FDA Approval in CLL, Recommendation in NSCLC, Missed Endpoint in GBM Study, and More   FDA Approval and Priority Review in Ovarian Cancer, End of Part B Payment Model, and More   FDA Approval in Lung Cancer, Priority Reviews in HCC and NHL, and an ODAC Recommendation   21st Century Cures Act Passes and 2016 Highlights from SABCS and WCLC   Dr. Grothey on FDA Approval of Pembrolizumab in MSI-High CRC   FDA Approval and 2 Priority Reviews in Bladder Cancer, and ASCO's Cancer Advance of the Year   Emerging ALK/ROS1 TKIs for NSCLC

Popular Today